SRR1474466
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.475
- BILE_ACID_METABOLISM+0.330
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.326
- PANCREAS_BETA_CELLS+0.316
- SPERMATOGENESIS+0.299
- ADIPOGENESIS+0.291
- FATTY_ACID_METABOLISM+0.262
- KRAS_SIGNALING_DN+0.254
- ESTROGEN_RESPONSE_LATE+0.250
- MYOGENESIS+0.188
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.414
- G2M_CHECKPOINT-0.401
- NOTCH_SIGNALING-0.399
- MITOTIC_SPINDLE-0.370
- MYC_TARGETS_V2-0.370
- E2F_TARGETS-0.313
- UNFOLDED_PROTEIN_RESPONSE-0.279
- INTERFERON_ALPHA_RESPONSE-0.272
- IL6_JAK_STAT3_SIGNALING-0.252
- TNFA_SIGNALING_VIA_NFKB-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1321046 | GTEX | — | 0.907 |
| 2 | SRR1318426 | GTEX | — | 0.895 |
| 3 | SRR1437306 | GTEX | — | 0.863 |
| 4 | SRR1315371 | GTEX | — | 0.859 |
| 5 | SRR1413959 | GTEX | — | 0.859 |
| 6 | SRR1415095 | GTEX | — | 0.857 |
| 7 | SRR1435293 | GTEX | — | 0.847 |
| 8 | SRR1420493 | GTEX | — | 0.845 |
| 9 | SRR1471817 | GTEX | — | 0.845 |
| 10 | SRR1323764 | GTEX | — | 0.838 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.475 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.330 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.326 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.316 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.299 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.291 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.262 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.254 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.250 | Idelalisib | — uncovered |
| MYOGENESIS | 0.188 | Inavolisib | — uncovered |
| PEROXISOME | 0.141 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.104 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.094 | Inavolisib | — uncovered |
| COAGULATION | 0.091 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.078 | Inavolisib | — uncovered |
| COMPLEMENT | 0.060 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.059 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.049 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.048 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.025 | Inavolisib | — uncovered |